Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Quince Therapeutics, Inc. - Common Stock (NQ: QNCX )

1.540 +0.080 (+5.48%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Quince Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
Quince Therapeutics to Participate at Upcoming Investor Conferences
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces The Lancet Neurology Publication of Phase 3 ATTeST Clinical Trial Data Evaluating EryDex for the Treatment of Ataxia-Telangiectasia (A-T)
From Quince Therapeutics, Inc.
Via Business Wire
Echo Lake Criticizes Quince Therapeutics Board for Enriching Themselves While Destroying Significant Shareholder Value
Via ACCESSWIRE
Biomed Industries, Inc. Offers to Acquire Quince Therapeutics, Inc.
Via ACCESSWIRE
Quince Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
From Quince Therapeutics, Inc.
Via Business Wire
Echo Lake Capital Offers to Acquire Quince Therapeutics, Inc.
Via ACCESSWIRE
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Launches Scientific Advisory Board
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Participate at Investor Events in January 2024
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Completes Acquisition of EryDel S.p.A.
From Quince Therapeutics, Inc.
Via Business Wire
U.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s Lead Phase 3 Asset EryDex for the Treatment of Ataxia-Telangiectasia
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Appoints Dr. Charles S. Ryan as President
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Present at Sidoti Virtual Investor Conference on August 17, 2023
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics to Acquire EryDel SpA and its Phase 3 Asset Targeting Ataxia-Telangiectasia with No Currently Approved Treatments and Estimated $1+ Billion Peak Sales Opportunity
From Quince Therapeutics, Inc.
Via Business Wire
Echo Lake Capital Increase Offer to Acquire Quince Therapeutics, Inc.
Via ACCESSWIRE
Quince Therapeutics Board of Directors Unanimously Rejects Unsolicited Proposal from Echo Lake Capital
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Engages MTS Health Partners as Independent Financial Advisor
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Adopts Limited Duration Stockholders Rights Plan
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Confirms Receipt of Unsolicited Acquisition Offer from Echo Lake Capital
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Provides Pipeline Update and Business Outlook for 2023
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Completes the Sale of Legacy Protease Inhibitor Portfolio to Lighthouse Pharmaceuticals
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Preclinical Data at MHSRS 2022 Demonstrating Preclinical Efficacy of Bone-targeting Platform for Traumatic Bone Injury
From Quince Therapeutics, Inc.
Via Business Wire
Quince Therapeutics Presents Preclinical Data at ASBMR 2022 Demonstrating Application of Bone-targeting Platform for Spinal Fusion and Bone Cancer Indications
From Quince Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.